The Conversation (0)
Tekmira Pharmaceuticals Corporation (TSX:TKM, NASDAQ:TKMR), a leading developer of RNA interference (RNAi) therapeutics, presented recent advances in its anti-viral product platform at the sixth International Symposium of Filoviruses in Galveston, Texas.
As quoted in the press release:
Tekmira’s Chief Technical Officer, Dr. Ian MacLachlan, presented new preclinical data showing 100% survival was achieved when dosing with TKM-Marburg at 0.5 mg/kg began 72 hours after infection with otherwise lethal quantities of the Marburg virus. Dosing then continued once daily for seven days. Earlier data from this collaborative research between Tekmira and the University of Texas Medical Branch (UTMB) showed 100% survival was achieved when dosing at 0.5 mg/kg TKM-Marburg began either one hour, 24 hours, or 48 hours after infection with otherwise lethal quantities of the virus. These studies represent the first known demonstration of protection of non-human primates from Marburg-Angola, the most lethal strain of Marburg virus. In February 2014, UTMB and Tekmira, along with other collaborators, were awarded additional funding from the National Institutes of Health (NIH) in support of this research.
Dr. Mark J. Murray, Tekmira’s President and CEO commented:
We are pleased to report more positive preclinical results validating the use of Tekmira’s LNP technology in our anti-viral product platform. These new data from our TKM-Marburg program demonstrate survival in non-human primates despite treatment being delayed until 72 hours after infection with otherwise lethal doses of Marburg virus.
Click here to read the Tekmira Pharmaceuticals (TSX:TKM,,NASDAQ:TKMR) press release
Click here to see the Tekmira Pharmaceuticals (TSX:TKM,,NASDAQ:TKMR) profile.